Form 4: Alkermes Executive David Gaffin Reports Stock Transactions

David Joseph Gaffin, EVP, CLO of Alkermes, reports acquisition and disposal of ordinary shares and derivative securities.

Summary

• On February 18, 2025, David Joseph Gaffin, EVP, CLO of Alkermes, engaged in transactions involving Alkermes plc. ordinary shares.
• Gaffin acquired 6,354 ordinary shares through the vesting of restricted stock units.
• He also disposed of 2,822 ordinary shares to cover tax obligations at a price of $35.9 per share.
• Following these transactions, Gaffin directly owns 192,031 ordinary shares.
• On February 19, 2025, Gaffin was granted an employee stock option to purchase 63,991 ordinary shares at a price of $35.84, which vests in four equal annual installments commencing on February 19, 2026, and expires on February 19, 2035.
• Gaffin was also granted 30,692 restricted stock units, which vest in four equal annual installments commencing on February 19, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions related to executive compensation.

Positives

• The granting of stock options and restricted stock units to an executive could be seen as a positive sign, aligning the executive's interests with those of the shareholders.

Negatives

• The disposal of shares to cover tax obligations could be interpreted as a slight negative, although it's a common practice.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest a continued commitment from the executive.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard components of executive compensation packages in the pharmaceutical industry, similar to companies like Biogen, Vertex Pharmaceuticals, and Gilead Sciences.
• The vesting schedules described are typical, often spanning several years to encourage long-term commitment.

Stakeholder Impact

• The transactions have a minor impact on shareholders, reflecting changes in insider ownership.
• Employees may be affected by the granting of stock options and restricted stock units, potentially boosting morale and aligning interests.

Key Dates

Keywords

Alkermes, Gaffin, stock options, restricted stock units, ordinary shares, Form 4, executive compensation, insider trading